Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
  • C07K7/04—Linear peptides containing only normal peptide links
  • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
  • C07K7/02—Linear peptides containing at least one abnormal peptide link
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K31/404—Indoles, e.g. pindolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/42—Oxazoles
  • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4245—Oxadiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
  • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
  • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
  • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
  • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
  • A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
  • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
  • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
  • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
  • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/06—Dipeptides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/06—Dipeptides
  • C07K5/06008—Dipeptides with the first amino acid being neutral
  • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
  • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/06—Dipeptides
  • C07K5/06008—Dipeptides with the first amino acid being neutral
  • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
  • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
  • C07K5/06052—Val-amino acid
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/06—Dipeptides
  • C07K5/06008—Dipeptides with the first amino acid being neutral
  • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
  • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
  • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
  • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
  • C07K2317/565—Complementarity determining region [CDR]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
  • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

• ADCs New binder-drug conjugates
• the present application relates to novel target mesothelin-targeting drug conjugates (ADCs) of N, N-dialkylauristatins, active metabolites of these ADCs, methods of making these ADCs, the use of these ADCs for the treatment and / or prevention of disease, and the use of these ADCs for the preparation of medicaments for the treatment and / or prevention of diseases, in particular hyperproliferative and / or angiogenic diseases such as, for example, cancer.
• diseases in particular hyperproliferative and / or angiogenic diseases such as, for example, cancer.
• Such treatments may be monotherapy or in combination with other medicines or other therapeutic measures.
• Cancers are the result of uncontrolled cell growth in a variety of tissues, in many cases the new cells invade existing tissues (invasive growth) or they metastasize to distant organs. Cancers occur in various organs and often have tissue-specific disease courses. Therefore, the term cancer as a generic term describes a large group of defined diseases of various organs, tissues and cell types
• chemotherapeutic agents administered parenterally today are often not targeted to tumor tissue or tumor cells, but are nonspecifically distributed in the body by systemic administration, i. even in places where drug exposure is undesirable, such as in healthy cells, tissues, and organs. This can lead to unwanted side effects and even serious general toxic effects, which then often severely limit the therapeutically usable dose range of the active substance or require a complete cessation of the medication.
• trastuzumab Herceptin
• rituximab Renitux
• cetuximab Erbitux
• bevacizumab Avastin
• small molecule drug binders can also be used as binders that bind selectively to a specific target, such as a receptor [see, e.g. E. Ruoslahti et al., Science 279, 377-380 (1998); D. Karkan et al., PLoS ONE 3 (6), e2469 (June 25, 2008)].
• a specific target such as a receptor
• conjugates of cytotoxic drug and addressing ligand which have a defined cleavage site between ligand and drug to release the drug.
• Such a "target breakpoint" may be, for example, in a peptide chain which can be selectively cleaved at a particular site by a specific enzyme at the site of action [see, e.g. R. A, Firestone and L.A. Telan, US Patent Application US 2002/0147138).
• HERCEPTIN® and Erbitux® are successfully used in the treatment of HER2-positive breast cancer and EGFR-positive colorectal cancer, respectively.
• cytotoxic compounds provides an expanded opportunity to further enhance cancer therapy because these conjugates allow for tumor-specific toxophore accumulation while reducing systemic toxicity.
• brentuximab vedotin in Hodgkin's lymphoma and trastuzumab-DMl in breast cancer have received promising results supporting the development of new antibodies and new ADCs against other tumor antigens.
• the mesothelin precursor polypeptide is a glycophosphatidyHnositol (GP1) anchored glycosylated cell surface protein which is proteolytically cleaved into a 30 kDa N-terminal secreted polypeptide (megakaryocyte potentiating factor, MPF) and a 40 kDa C-terminal polypeptide anchored predominantly at the GPI Cell membrane (mesothelin) (Chang, K. and L Pastan, Proc. Natl. Acad. Sci. Ii SA, (1996) 93 (1): 136).
• GP1 glycophosphatidyHnositol
• mesothelin represents a suitable antigen for monoclonal antibody therapy.
• the exact function of mesothelin is hitherto unknown, mesothelin-gene deficient mice show no apparent anatomical, hematological or reproduction-limiting abnormalities (Bera, TK and I. Pastan, Mol. Cell. Biol.
• mesothelin is a highly variable protein undergoing posttranlational modifications such as proteolytic digestion and glycosylations (Hassan, R., et al., Clin. Cancer Res. (2004) 10 (12 Pt 1): 3937).
• Therapeutic antibodies should therefore recognize an invariant epitope independently of the individual mesothelin modifications.
• Antibodies may be purified according to their desired properties, e.g. invariant affinity or intemalization, whereby the use of monoclonal antibodies guarantees that these properties apply on the one hand to all antibodies and on the other hand can be consistently produced in the long term.
• Auristatin E (AE) and monomethylauristatin E (MMAE) are synthetic analogues of the dolstatins, a special group of linear pseudopeptides originally isolated from marine sources, some of which have potent cytotoxic activity against tumor cells [for a review, see, eg GR Pettit, Prague. Chem. Org. Prod. 70, 1-79 (1997); GR Pettit et al, Anti-Cancer Drag Design 10, 529-544 (1995); GR Pettit et al, AntiCancer Drug Design 13, 243-277 (1998) 1.
• MMAE Monomethylauristatin E
• MMAE has the disadvantage of a comparatively high systemic toxicity.
• MMAE is used in particular in conjunction with enzymatically cleavable valine citrulline linkers in the ADC setting for more targeted tumor therapy [WO 2005/081711 -A2; S.O. Doronina et al, Bioconjugate Chem, 17, 114-124 (2006)].
• MMAE is preferably released intracellularly from corresponding ADCs.
• MMAE is not compatible with linking moieties (linkers) between binder and drug that do not have an enzymatically cleavable sol-breakpoint [S. Doronina, et al., Bioconjugate Chem., 17, 114-124 (2006)].
• Monomethylauristatin F is an auristatin derivative having a C-terminal phenylalanine moiety that has only moderate anti-proliferative activity as compared to MMAE. This is most likely due to the free carboxyl group, which negatively influences the cellularity of this compound due to its polarity and charge.
• MMAF-OMe methyl ester of MMAF
• MMAF-OMe methyl ester of MMAF
• MMAF-OMe has been described as a neutrally charged, prodrug prodrug, which has several orders of magnitude increased in vitro cytotoxicity to various carcinoma cell lines compared to MMAF [SO Doronina et al., Bioconjugate Chem. 17, 114-124 (2006)]. It is believed that this effect is caused by MMAF itself, which is rapidly released by intracellular ester hydrolysis after uptake of the prodrug into the cells.
• MMAF MonoiTiethyiauristatin F
• active compound compounds based on simple ester derivatives are generally subject to the risk of chemical instability as a result of unspecific ester hydrolysis independent of the intended site of action, for example by esterases present in the blood plasma; this can significantly limit the applicability of such compounds in therapy.
• MMAF Monomethylauristatin F
• auristatin analogues with a C-terminal, amidically substituted phenylalanine unit are described in WO 01/18032-A2.
• WO 02/088172-A2 and WO 2007/008603-A1 claim MMAF analogs which relate to side-chain modifications of phenylalanine, and in WO 2007/008848-A2 those in which the carboxyl group of phenylalanine is modified , Auristatin conjugates linked via the C-terminus have recently been described in WO 2009/1 17531 -AI [see also S.O. Doronina et al., Bioconjugate Chem. 19, 1960-1 963 (2008) 1.
• auristatin derivatives such as MMAE and MMAF are also substrates for transporter proteins which are expressed by many tumor cells, which can lead to a development of resistance to these active substances.
• ADCs novel binder-drug conjugates
• the present invention relates to binder-active compound conjugates of the general formula (Ia)
• n stands for a number from 1 to 50
• AK stands for a binder
• group ⁇ -GL 1 -BL 2 - ⁇ stands for a linker
• ⁇ denotes the point of attachment with the group AK and ⁇ denotes the point of attachment with the nitrogen atom, D represents a group of the formula
• R 1 is hydrogen or methyl
• R 2 is isopropyl, isobutyl, sec-butyl, fer-.-Butyl, phenyl, benzyl, 1-hydroxyethyl, 4-
• # 5 denotes the point of attachment with the carbonyl group, the ring A with the NO group contained therein for a mono- or bicyclic, optionally substituted heterocycle of the formula
• R 6 is hydrogen, hydroxy or benzyloxy
• R 3 is hydrogen or methyl
• R 4 is isopropyl, isobutyl, sec-butyl, fer-butyl, phenyl, benzyl, 1-hydroxyethyl, 4-hydroxybenzyl, 4-hydroxy-3-nitrobenzyl, 4-hydroxy-3-aminobenzyl, 1-phenylethyl, Diphenylmethyl, 1H-imidazol-4-ylmethyl or 1H-indol-3-ylmethyl. or R J and R 4 together with the carbon atom to which they are attached form a (15,2R) -2-phenylcyclopropane-1,1-diyl group of the formula
• R ' is hydrogen, methyl, ethyl, w-propyl, tert-butyl, benzyl or adamantylmethyl,
• R 8 is hydrogen or methyl
• R 9 is hydrogen, methyl, ethyl, propyl or benzyl, or
• R 8 and R 9 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycle
• R i 0 is benzoyl
• R 11 is benzyl, which may be substituted in the phenyl group with methoxycarbonyl or carboxyl, is hydrogen, methyl or a group of the formula
• R 12 is phenyl which is reacted with methoxy-carbonyl, carboxyi or a group of the formula Si i j.
• CM i can be substituted
• R 13 is phenyl which may be substituted by methoxy-carbonyl or carboxy,
• R 26 is hydrogen or hydroxy
• T 2 is phenyl, benzyl, 1H-indol-3-yl or 1H-indol-3-ylmethyl, R 35 is methyl or hydroxy, and their salts, solvates and solvates of the salts.
• Compounds of the invention are the compounds of the formula (ia) and (I) and their salts, solvates and solvates of the salts, the compounds of the formulas (Ia) and (I) of the following formulas and their salts, solvates and solvates of the salts and the compounds of formula (Ia) and (I), referred to below as exemplary embodiments, and their salts, solvates and solvates of the salts, as far as the compounds of formula (Ia) and (I) below are not already salts , Solvates and solvates of the salts.
• the compounds according to the invention can exist in different stereoisomeric forms, ie in the form of configurational isomers or optionally also as conformational isomers (enantiomers and / or diastereomers, including those in the case of atropisomers).
• the present invention therefore includes the enantiomers and diastereoisomers and their respective mixtures.
• the stereo isomer employed for this, in particular HPLC chromatography on achiral or chiral phase.
• the present invention encompasses all tautomeric forms.
• the present invention also includes all suitable isotopic variants of the compounds of the invention.
• An isotopic variant of a compound according to the invention is understood here as meaning a compound in which at least one atom within the compound according to the invention is exchanged for another atom of the same atomic number but with a different atomic mass than the atomic mass that usually or predominantly occurs in nature.
• isotopes which can be incorporated into a compound of the invention are those of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine and iodine, such as 2 H (deuterium), 3 H (tritium), 13 C, 14 C, 15 N, 17 0, 18 0, 32 P, 33 P, 3 S, 34 S, 35 S, 36 S, 18 F, 6 Ci, 82 Br, i23 L ! 24 I, 129 1 and i3l I.
• Certain isotopic variants of a compound of the invention may be useful, for example for the study of the mechanism of action or distribution of active ingredient in the body; Due to the comparatively easy production and detectability, compounds labeled with 3 H or 14 C isotopes are particularly suitable for this purpose.
• isotopes such as deuterium may result in certain therapeutic benefits as a result of greater metabolic stability of the compound, such as prolonging the body's half-life or reducing the required effective dose;
• isotopic variants of the compounds according to the invention can be prepared by the processes known to the person skilled in the art, for example by the methods described below and the rules given in the exemplary embodiments, by corresponding Isotopic modifications of the respective reagents and / or starting compounds can be used.
• Salts used in the context of the present invention are physiologically acceptable salts of the compounds according to the invention. Also included are salts which are themselves unsuitable for pharmaceutical applications but can be used, for example, for the isolation or purification of the compounds of the invention.
• Physiologically acceptable salts of the compounds according to the invention include acid addition salts of mineral acids, carboxylic acids and sulfonic acids, for example salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, naphthalenedisulfonic acid, acetic acid, trifluoroacetic acid. acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid, maleic acid and benzoic acid.
• Physiologically acceptable salts of the compounds according to the invention also include salts of customary bases, such as, by way of example and by way of preference, alkali metal salts (for example sodium and potassium salts), alkaline earth salts (for example calcium and magnesium salts) and ammonium salts derived from ammonia or organic amines having from 1 to 16 carbon atoms.
• alkali metal salts for example sodium and potassium salts
• alkaline earth salts for example calcium and magnesium salts
• ammonium salts derived from ammonia or organic amines having from 1 to 16 carbon atoms such as, by way of example and by way of preference, alkali metal salts (for example sodium and potassium salts), alkaline earth salts (for example calcium and magnesium salts) and ammonium salts derived from ammonia or organic amines having from 1 to 16 carbon atoms.
• Atoms such as, by way of example and by way of preference, ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, N-methylpiperidine, N-methylmorpholine, arginine, lysine and 1,2-ethylenediamine.
• Solvates in the context of the invention are those forms of the compounds according to the invention which form a complex in the solid or liquid state by coordination with solvent molecules. Hydrates are a special form of solvates that coordinate with water. As solvates, hydrates are preferred in the context of the present invention.
• the present invention also includes prodrugs of the compounds of the invention.
• prodrugs refers to compounds which themselves may be biologically active or inactive, but are converted during their residence time in the body to compounds of the invention (for example metabolically or hydrolytically).
• (C 1 -C 4 -alkyl in the context of the invention represents a linear or branched alkyl radical having 1 to 4 carbon atoms, by way of example and preferably: methyl, ethyl, propyl, isopropyl, ⁇ -butyl, isobutyl, 1-methylpropyl and teri. butyl.
• (C 1 -C 4 -alkylcarbonyl in the context of the invention is a linear or branched alkyl radical having 1 to 4 colilenic atoms which is linked via a carbonyl group, by way of example and by preference: methylcarbonyl, ethylearbonyi, "-propylcarbonyl, isopropylcarbonyl," -butylcarbonyl, Isobutylcarbonyl, 1-methylpropylcarbonyl and tert-butylcarbonyl.
• Aikandiyl is in the context of the invention for a linear, ⁇ , ⁇ -divalent alkyl radical having the particular specified number of carbon atoms.
• Examples which may be mentioned by way of example and with preference are: methylene, ethane-1,2-diyl (1,2-ethylene), propane-1,3-diyl (1,3-propylene), butane-1,4-diyl (1,4,9) Butylene), pentane-l, 5-diyl (1,5-pentylene), hexane-1, 6-diyl (1,6-hexylene), heptane-l, 7-diyl (1, 7 Hexylene ⁇ , octane, 8-diyi (1,8-octylene), nonane-l, 9-diyl (1, 9-nonylene), decane-l, 10-diyl (1, 10-decylene).
• (C 1 -C 4 -cycloalkyl or 3 to 7-membered carbocycle in the context of the invention represents a monocyclic, saturated cycloalkyl group having 3 to 7 carbon atoms, by way of example and preferably: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
• the side group of an ⁇ -amino acid in the meaning of R 1 " includes both the side groups of the naturally occurring ⁇ -amino acids and the side groups of homologues and isomers of these ⁇ -amino acids in the D configuration or as a mixture of the L and D.
• side groups which may be mentioned by way of example are: methyl (alanine), propan-2-yl (valine), propan-1-yl (norvaline), 2 Methylpropane-1-yl (leucine), l-methylpropan-1-yl (isoleucine), butan-1-yl (norleucine), ferric butyl (2-yl-butylglycine), phenyl (2-phenylglycine) , Benzyl (phenylalanine), p-hydroxybenzyl (tyrosine), indol-3-ylmethyl (tryptophan), imidazol-4-ylmethyl (histidine), hydroxymethyl (serine), 2-hydroxyethyl (homoserine), 1-hydroxyethyl (threonine ), Mercaptomethyl (cysteine), methylthiomethyl (S-methylcysteine), 2-mercaptoethyl (homocysteine), 2-methylthioethyl
• Preferred ⁇ -amino acid side groups in the meaning of R 19 are methyl (alanine), propan-2-yl (valine), 2-methylpropan-1-yl (leucine), benzyl (phenylalanine), imidazol-4-ylmethyl (Histidine), hydroxymethyl (serine), 1-hydroxyethyl (threonine), 4-aminobutan-1-yl (lysine), 3-aminopropan-1-yl (ornithine), 2-aminoethyl (2,4-diaminobutyric acid), aminomethyl (2,3-diaminopropionic acid), 3-guanidinopropan-1-yl (arginine).
• the L configuration is preferred in each case.
• a 4- to 7-membered heterocycle is in the context of the invention for a monocyclic saturated heterocycle having a total of 4 to 7 ring atoms containing one or two ring heteroatoms from the series N, O, S, SO and / or SO 2 and is linked via a ring carbon atom or optionally a ring nitrogen atom.
• Preference is given to a 5- to 7-membered heterocycle having one or two ring heteroatoms from the series, O and / or S, particularly preferably one.
• 5H or 6-membered heterocycle having one or two ring heteroatoms from the series N and / or O.
• Examples include: azetidinyl, oxetanyl, pyrrolidinyl, pyrazolidinyl, tetrahydrofuranyl, thiolane, Piperidinvl, piperazinyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholinyl, thio-mo ⁇ holinyl , Hexahydroazepinyl and hexahydro-1,4-diazepinyl. Preference is given to pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyranyl and ⁇ ⁇ ⁇ .
• radicals are substituted in the compounds according to the invention, the radicals can, unless otherwise specified, be monosubstituted or polysubstituted. Substitution with one or two identical or different substituents is preferred. Particularly preferred is the substitution with a substituent.
• linker is broadly understood to mean a chemical entity comprising a covalent bond or an array of atoms that covalently attaches a binder to an agent, Preferably, the term “linker” is used as an array of atoms in the sense of Understand the present invention, which covalently attaches a binder to a drug.
• linkers may be, for example, divalent chemical moieties such as alkyldiyls, aryldiyls, heteroaryldyls, heterocyclyldyls, dicarbonylic acid esters, dicarbonylic acid amides.
• binder is broadly understood to mean a molecule that binds to a target molecule present on a particular target cell population to be targeted with the binder-drug conjugate.
• binder is to be understood in its broadest interpretation and includes, for example, lectins, proteins that bind certain sugar chains, or phospholipid-binding proteins, such as high molecular weight proteins (binding proteins), polypeptides or peptides (binding peptides), non-peptidic (eg, aptamers (US5,270,163) review articles by Keefe AD Rev. Drug Disco v.
• Binding peptides are, for example, ligands of a ligand-receptor pair, such as VEGF of the ligand-receptor pair VEGF / KDR, such as transferrin of the ligand receptor pair transferrin / 'transferrin receptor or cytokine / cytokine receptor, such as TNFalpha of the ligand-receptor pair TNFalpha TNFalpha receptor.
• ligands of a ligand-receptor pair such as VEGF of the ligand-receptor pair VEGF / KDR
• transferrin of the ligand receptor pair transferrin / 'transferrin receptor or cytokine / cytokine receptor, such as TNFalpha of the ligand-receptor pair TNFalpha TNFalpha receptor.
• Preferred binders according to the invention are (in particular human, monoclonal antibodies or antigen-binding antibody fragments which bind to mesothelin.)
• n ie the number of toxophore molecules per antibody molecule, is preferably in the range from 1 to 10 , more preferably 2 to 8.
• a "target molecule” is broadly understood to be a molecule that is present in the target cell population, and may be a protein (eg, a growth factor receptor) or a non-peptidic molecule (eg, a sugar or Phospholipid), preferably a receptor or an antigen.
• extracellular target molecule describes a cell-bound target molecule located on the outside of a cell or the portion of a target molecule that is on the outside of a cell, ie, a binder can bind to an extracellular target molecule on an intact cell
• An extracellular target molecule can be anchored in the cell membrane or be part of the cell membrane
• the person skilled in the art knows methods for identifying extracellular target molecules For proteins, this can be done by determining the transmembrane domain (Q) and the orientation of the protein in the membrane Information is usually stored in protein databases (eg SwissProt).
• cancer target molecule describes a target molecule that is more abundant on one or more types of cancer cells compared to non-cancerous cells of the same tissue type, Preferably, the cancer target molecule is on one or more cancer cell types compared to non-cancer cells of the same tissue type selectively present, selectively describing at least two-fold accumulation on cancer cells as compared to non-cancer cells of the same tissue type (a "selective cancer target molecule”).
• the use of cancer targeting molecules allows the selective therapy of cancer cells with the conjugates of the invention.
• the binder can be linked via a linkage with the linker.
• Various possibilities of covalent coupling (conjugation) of organic molecules to antibodies are known from the literature.
• the linkage of the binder can be effected by means of a heteroatom of the binder.
• Heterocycles of the invention which can be used for linking are sulfur (in one embodiment via a sulfhydryl group of the binder), oxygen (according to the invention by means of a carboxyl or hydroxyl group of the binder) and nitrogen (in one embodiment via a primary or secondary amine group or amide group of the Binders).
• the conjugation of the toxophore to the antibody is preferably via one or more sulfur atoms of cysteine residues of the antibody and / or via one or more NH groups of lysine residues of the antibody.
• the linkage of the binder with the toxophore has only a small influence on the binding activity of the binder to the target molecule. In a preferred embodiment, the linkage has no influence on the binding activity of the binding agent to the target molecule.
• the term "antibody” is understood in its broadest sense according to the present invention and includes immunoglobulin molecules, for example intact or modified monoclonal antibodies, polycionic antibodies or multispecific antibodies (eg bispecific antibodies).
• An immunoglobulin molecule preferably comprises a molecule having four polypeptide chains, two heavy chains (H chains) and two light chains (L chains), which are typically linked by disulfide bridges.
• Each heavy chain comprises a heavy chain variable domain (abbreviated VH) and heavy chain constant domain.
• the heavy chain constant domain may include three domains CHI, CH2, and CID.
• Each light chain comprises a variable domain (VI for short) and a constant domain.
• the constant domain of the light chain comprises a domain (abbreviated to CL).
• the VH and VL domains can be further subdivided into regions of Ilypervariabity, also called complementarity determining regions (abbreviated to CDR) and regions of lower sequence variability (FR).
• CDR complementarity determining regions
• FR regions of lower sequence variability
• an antibody can be obtained from any suitable species, eg, rabbit, llama, camel, mouse, or rat.
• the antibody is of human or murine origin.
• an antibody can be human, humanized or chimeric.
• monoclonal antibody refers to antibodies that would be obtained from a population of substantially homogeneous antibodies, ie, individual antibodies of the population are identical except for naturally occurring mutations that may occur in small numbers. "Monoclonal antibodies recognize with high specificity a single antigenic binding site The term monoclonal antibody does not refer to a particular manufacturing process.
• the term "intact" antibody refers to antibodies comprising both an antigen-binding domain and the light and heavy chain constant domain
• the constant domain may be a naturally occurring domain, or a variant thereof in which multiple amino acid positions are altered were.
• modified intact antibody refers to intact antibodies that have been linked to another non-antibody polypeptide or protein via their amino terminus or carboxy terminus by means of a covalent bond (eg Peptide linkage ⁇ were excised.
• antibodies can be modified to introduce reactive cysteines at defined sites to facilitate coupling to a toxophore (see Junutula et al., Nai Biotechnol., 2008 Aug; 26 (8): 925-32).
• human antibody refers to antibodies that can be obtained from a human or that are synthetic human antibodies
• a "synthetic” human antibody is an antibody that is available, in part or in whole, from synthetic sequences in silico that have been analyzed based on human antibody sequences.
• a human antibody can e.g. be encoded by a nucleic acid isolated from a library of antibody sequences of human origin. An example of such antibodies is in Söderlind et al., Nature Biotech. 2000, 18: 853-856.
• humanized or “chimeric” antibody describes antibodies consisting of a non-human and a human sequence portion. In these antibodies, part of the sequences of the human immunoglobulin (recipient) is replaced by sequence portions of a non-human immunoglobulin (donor).
• the donor is a murine immunoglobulin in many cases.
• amino acids of the CDR of the recipient are replaced with amino acids of the donor. Sometimes amino acids of the framework are replaced by corresponding amino acids of the donor.
• the humanized antibody contains amino acids that were not contained in either the recipient or the donor and that were inserted during optimization of the antibody.
• the variable domains of the donor immunoglobulin are fused to the constant regions of a human antibody.
• complementarity determining region refers to those amino acids of a variable antibody domain necessary for binding to the antigen.
• Each variable region typically has three CDR regions, referred to as CDR1, CDR2 and CDR3.
• Each CDR region may include amino acids as defined by Kabai and / or amino acids of a hypervariable loop defined by Chotia.
• the Kabat definition includes, for example, the region of approximately amino acid position 24-34 (CDR1), 50-56 (CDR2) and 89-97 (CDR3) of the variable light chain and 31-35 (CDR1), 50-65 (CDR2).
• CDR3 variable heavy chain Kabat et al., Sequences of Proteins of Immulological Interest, 5th Ed, Public Health Services, National Institutes of Health, Bethesda, MD. (1991)).
• the definition according to Chotia includes, for example, the region of approximately amino acid position 26-32 (CDR1), 50-52 (CDR2) and 91-96 (CDR3) of the variable light chain and 26-32 (CDR1), 53-55 (CDR2). and 96-101 (CDR3) of the variable heavy chain Chothia and Lesk; J Mol Bio! 196: 901-917 (1987)).
• a CDR may comprise amino acids from a CDR region as defined by Kabat and Chotia.
• antibodies can be divided into different classes. There are five major classes of intact antibodies: IgA, IgD, IgE, IgG and IgM, several of which can be subdivided into further subclasses, (isotypes), e.g. IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2.
• the heavy chain constant domain corresponding to the different classes are referred to as [alpha / a], [delta / ⁇ ], [epsilon ⁇ ], [gamma / ⁇ ] and [my / ⁇ ]. Both the three-dimensional structure and the subunit structure of antibodies are known.
• the term "functional fragment” or "antigen binding” of an antibody immunoglobulin is defined as a fragment of an antibody / immunoglobulin (eg, the variable domains of an IgG) which still comprises the antigen binding domains of the antibody / immunoglobulin
• the "antigen-binding domain” of an antibody typically comprises one or more hypervariable regions of an antibody, eg the CDR, CDR2 and / or CDR3 region.
• the "framework” or “framework” region of an antibody may also play a role in binding the antibody to the antigen.
• the framework region provides the framework for the CDRs.
• the antigen-binding mandarin comprises at least amino acids 4 to 103 of the variable light chain and amino acids 5 to 109 of the variable heavy chain, more preferably amino acids 3 to 107 of the variable light chain and 4 to 11 of the variable heavy chain are particularly preferred the complete variable light and heavy chains, so amino acid 1 - 109 of the VL and 1 to 1 13 of the VH (numbering according to WO97 / 08320).
• “Functional fragments” or “antigen-binding antibody fragments” of the invention do not exhaustively include Fab. Fab ', F (ab') i and Fv fragments, diabodies, single domain antibodies (DAbs), linearae antibodies, single chain antibodies (single-chain Fv, abbreviated scFv); and multispecific, such as bi- and tri-specific, antibodies formed from antibody fragments CA K Borrebaeck, editor (1995) Antibody Engineering (Breakthroughs in Molecular Biology), Oxford University Press; R. Kontermann & S. Duebel, editors (2001) Antibody Engineering (Springer Laboratory Manual), Springer Verlag). Antibodies other than "multi-specific” or “multi-functional” are those with identical binding sites.
• Multispecific antibodies may be specific for different epitopes of an antigen or specific for epitopes of more than one antigen (see, for example, WO 93/17715, WO 92/08802, WO 91/00360, WO 92/05793, Tuit, et al., 1991 , J. Immunol., 147: 60 69; U.S. Patent Nos. 4,474,893; 4,7 14,68 1; 4,925,648; 5,573,920; 5,601,819; or Kostelny et al., 1992, J. Immunol. 148: 1547 1553 ).
• An F (ab ') 2 or Fab molecule can be constructed so that the number of intermolecular disulfide Interactions that take place between the Ch i and the CL domains can be reduced or completely prevented.
• “Functional fragments” or “antigen-binding antibody fragments” may be fused to another polypeptide or protein that is not derived from an antibody via its amino terminus or carboxy-terminus via a covalent bond (e.g., a peptide linkage).
• antibodies and antigen-binding fragments can be modified to introduce reactive cysteines at defined sites to facilitate coupling to a toxophore (see Junutula et al., Nat Biotechnol., 2008 Aug; 26 (8); 925-32)
• Polyclonal antibodies can be prepared by methods known to those of ordinary skill in the art
• Monoclonal antibodies can be prepared by methods known to those of ordinary skill in the art (Köhler and Milstein, Nature, 256, 495-497, 1975)
• Humanized humanized monoclonal antibodies can be produced by those skilled in the art are known (Olsson et al., My Enzymol 92, 3-16 and Cabilly et al., US 4,816,567 or Boss et al US 4,816,397).
• Antibodies of the invention may be obtained from recombinant antibody libraries, for example, consisting of the amino acid sequences of a variety of antibodies generated from a large number of healthy volunteers. Antibodies can also be made by known recombinant DNA technology. The nucleic acid sequence of an antibody can be obtained by routine sequencing, or is available from publicly available databases.
• an “isolated” antibody or binder has been purified from other components of the cell Contaminating components of a cell which may interfere with a diagnostic or therapeutic use are, for example, enzymes, hormones, or other peptidic or non-peptidic components of a cell an antibody or binder which has been purified to more than 95% by weight, based on the antibody or binder (determined, for example, by Lowry method, UV-Vis spectroscopy or by SDS capillary gel electrophoresis.)
• an antibody is usually produced by one or more purification steps.
• specific binding refers to an antibody or binder that binds to a predetermined antigen / target molecule.
• Specific binding of an antibody or binder typically describes an antibody or binding with an affinity of at least 10 "7 M (as Kd value, so preferably those with smaller Kd values than 10" 7 M), wherein the antibody or a binder has at least two fold higher affinity for the predetermined antigen / target molecule than for a non-specific antigen / target molecule (eg, bovine serum albumin, or Caseisi) which is not the predetermined antigen / target molecule or a closely related antigen / target molecule.
• a non-specific antigen / target molecule eg, bovine serum albumin, or Caseisi
• Antibodies specific for a cancer cell antigen may be prepared by those of ordinary skill in the art by methods known to those skilled in the art (such as recombinant expression) or may be purchased commercially (e.g., from Merck KGaA, Deustchland). Examples of known commercially available antibodies in cancer therapy are Erbitux® (Cetuximab, Merck KGaA), Avastin® (Bevacizumab, Roche) and Herceptin® (Trastuzumab, Genentech).
• the antibody is produced recombinantly in CHO cells.
• the compounds of the formula (I) represent a subgroup of the compounds of the formula (Ia).
• Preferred subject matter of the invention are bin der-Wirk Sto f conjugates of general formula (Ia), in which n is a number from 1 to 50, AK for AK, or AK 2 is
• AKi for a binder (preferably an anti-mesothelin antibody) bound to the group G via a sulfur atom of the binder
• AK 2 for a binder (preferably an anti-Mesothelin Anii redesign), which is bound via a nitrogen atom of the binder to the group G.
• G for the case that AK AKi, for a group of Fonnel
• n is a number from 2 to 6
• R 33 represents hydrogen, (C 1 -C 4) -alkylcarbonyl, tert-butyloxycarbonyl or benzyloxycarbonyl,
• R 34 is hydrogen or methyl
• R 29 is hydrogen or R 30 is hydrogen or (C 1 -C 4) -alkyl, or
• R 29 and R 30 together with the atoms to which they are attached form a 5- or 6-membered heterocycle,
• R 3! is hydrogen or (C 1 -C 4) -alkyl,
• R 32 is hydrogen or (C 1 -C 4 -alkyl or
• R 31 and R 3 together with the atoms to which they are attached form a 5- or 6-membered heterocycle
• L ' B is linear (C 2 -C 10) -alkanediyl, and wherein (C 1 -C 10) -alkandiyi may be substituted by 1 to 4 substituents independently of one another selected from the group consisting of methyl, hydroxy and benzyl, and wherein two carbon atoms of the alkanediyl Chain in 1, 2, 1, 3 or 1, 4 relation to each other, including the carbon atoms optionally between them can be bridged to a (Cs-Cej-Cycioalkyl ring or a phenyl ring, for a bond or a Group of formula
• the point of attachment is L 1
• the point of attachment is L, O or NH
• L 3 is a bond or (C 2 -C 4) -alkanediyl. for a bond or a group of the formula
• point of attachment to the carbonyl group is characterized. denotes the point of attachment to L 2 , is hydrogen or methyl.
• R S represents hydrogen, (Ci-C4) alkylcarbonyl, tert-butyloxycarbonyl or benzyloxycarbonyl,
• Q 1 represents a 4- to 7-membered heterocyci
• R 14 is hydrogen or (Ci-C 4 ) -alkyl
• R ! 5 represents hydrogen or (C 1 -C 4 ) -alkyl
• R 14 and R 13 together with the atoms to which they are attached form a 5- or 6-membered heterocycle
• R 16 represents hydrogen or (C 1 -C 4 ) -alkyl
• R 17 is hydrogen or (Ci-C 4 ) -alkyl, or
• R 16 imd 17 together with the atoms to which they are attached form a 5- or 6-membered heterocycle
• R 18 is hydrogen or (C 1 -C 4 ) -alkyl
• R 19 represents hydrogen or the side group of a natural ⁇ -amino acid or its homologs or isomers
• R 20 is hydrogen or (Ci-C) -alkyl, or
• R 21 is hydrogen or (C 1 -C 4) -alkyl
• R 22 is hydrogen or (Ci-C 4 ) -alkyl, or
• R 2i and R 22 together with the atoms to which they are attached form a 3- to 7-membered carbocycle
• R 23 is (C 1 -C 4 ) -alkyl
• R 24 is hydrogen or (Ci-C 4 ) -alkyl
• R 27 is hydrogen or (Ci-C) -A! Ky! stands.
• R j6 represents hydrogen, (C 1 -C 4) -alkylcarbonyl, tert-butyloxycarbonyl or benzyloxycarbonyl,
• R 37 is hydrogen or methyl
• L 2 is linear (C 2 -C 10) -alkanediyl or a group of the formula where p is a number from 2 to 6,
• ## 3 denotes the point of attachment to the group B
• (C. 2 -C) -alkanediyl having 1 to 4 substituents selected independently of one another from the group consisting of methyl, hydroxy and benzyl can be substituted, and where two carbon atoms of the alkanediyl chain are in 1,2-, 1,3- or 1 , 4-relation to each other, including the optionally lying between them Kohienstoffatome to a (C3-C6) -cycloalkyl ring or a phenyl ring may be bridged,
• R 2 is for isopropyl, isobutyl, ⁇ -butyl, tert-butyl, phenyl, benzyl, 1-hydroxyethyl, 4-hydroxybenzyl, 4-hydroxy-3-nitrobenzyl, 4-hydroxy-3-aminobenzyl, 1-phenyl ethyl, diphenylmethyl, 1H-lxiidazol-4-ylmethyl or 1H-indol-3-ylmethyl, or
• # 5 denotes the point of attachment with the Carbonyi group, the ring A with the -0- moiety contained therein for a mono- or bicyclic, optionally substituted heterocycle of the formula
• R 6 is hydrogen, Ffydroxy or benzyloxy
• R J is hydrogen or methyl
• R 4 is isopropyl, isobutyl, sec-butyl, tert-butyl, phenyl, benzyl, 1-hydroxyethyl, 4-hydroxybenzyl, 4-hydroxy-3-nitrobenzyl, 4-hydroxy-3 aminobenzyl, 1-phenylethyl, diphenylmethyl, 1H-imidazol-4-ylmethyl or 1/7-mdol-3-ylmethyl, or
• R 7 is hydrogen, methyl, ethyl, w-propyl, tert-butyl, benzyl or adamantylmethyl,
• R 8 is hydrogen or methyl
• R 9 is hydrogen, methyl, ethyl, n-propyl or benzyl, or
• R 8 and R 9 form together with the. Nitrogen atom to which they are attached, a 4- to 7-membered heterocycle,
• R i0 is benzoyl.
• R ' 1 for benzyl which may be substituted in the Phenyi juxtapos with Methoxyearbonyi or Carboxyi, is hydrogen, methyl or a group of the formula
• point of attachment is -CHC (R 26 ) -T 2 , is phenyl which may be substituted with metlioxycarbonyl, carboxyi or a group of the formula -S (O) 20H, is phenyl substituted with methoxyearbonyi or carboxyi may be substituted
• R 26 is hydrogen or hydroxy
• T 2 is phenyl, benzyl, 1H-indol-3-yl or 1H-indol-3-ylmethyl,
• R 35 is methyl or hydroxy, and their salts, solvates and solvates of the salts.
• Preferred subject matter of the invention are binder-active compound conjugates of the general formula (Ia) in which n stands for a number from 1 to 50, AK for AK] or ⁇ K
• AK for a binder bound to the group G via a sulfur atom of the binder
• AK2 for a binder bound to the group G via a nitrogen atom of the binder
• n is a number from 2 to 6
• ## 1 denotes the point of attachment to the group G
• L iA is linear (C 2 -C 10) -alkanediyl
• R 33 is hydrogen, (C 1 -C 4) -alkylcarbonyl, tert-butyloxycarbonyl or benzyloxycarbonyl,
• R 34 is hydrogen or methyl
• R 29 is hydrogen or (C 1 -C 4) -alkyl
• R 30 is hydrogen or (C 1 -C 4) -alkyl
• R 29 and 30 together with the atoms to which they are attached form a 5- or 6-membered heterocycle, R 3! is hydrogen or (Ci-G alkyl, R 32 is hydrogen or stands, or
• R 31 and R 3 together with the atoms to which they are attached form a 5- or 6-g-lower heterocycle
• L lB is linear (C 2 -C 10) -alkanediyl, and wherein (C 1 -C 10) -alkandiyi may be substituted with 1 to 4 substituents independently selected from the group of methyl, hydroxy and benzo, and where two carbon atoms of the aikandiyl Chain in 1, 2, 1, 3 or 1,4 relative to each other, with the inclusion of any carbon atoms between them may be bridged to a (Cs-Cej-cycloalkyl ring or a phenyl ring, for a bond or a Group of Fonnel
• R 25 is hydrogen or methyl
• R 28 is hydrogen, (C 1 -C 4) -alkylcarbonyi, tert-butyloxycarbonyl or benzyloxycarbonyl,
• Q 1 is a 4- to 7-membered heterocycle
• Q 2 is a 3- to 7-membered carbocycle or a 4- to 7-membered heterocycle
• R 14 is hydrogen or (Ci-CVj-alkyl
• R 15 is hydrogen or (Ci-G alkyl, or
• R 1 and R 1 * together with the atoms to which they are attached form a 5- or 6-membered heterocycle
• R 16 is hydrogen or stands
• R 17 is hydrogen or (Ci-C 4 ) alkyl. or
• R 16 and R 17 together with the atoms to which they are attached form a 5- or 6-membered heterocycle
• R 18 is hydrogen or (C 1 -C 4 ) -alkyl
• R 19 is hydrogen or the side group of a natural ⁇ -amino acid or its
• R 20 is hydrogen or (C 1 -C 4 ) -alkyl, or
• R 2i is hydrogen or (C 1 -C 4 ) -alkyl
• R 22 is hydrogen or (Ci-C 4 ) -alkyl, or
• R zl and R z2 together with the atoms to which they are attached form a 3- to 7-membered carbocycle
• R 23 is (C 1 -C 4 ) -alkyl
• R 24 is hydrogen or (C 1 -C 4 ) -alkyl
• R 27 is hydrogen or (C 1 -C 4 ) -alkyl
• R 36 represents hydrogen, (C 1 -C 4 ) -alkylcarbonyl, tert-butyloxycarbonyl or benzyloxycarbonyl,
• R 37 is hydrogen or methyl
• ## 3 denotes the point of attachment to the group B
• # 3 denotes the point of attachment to the nitrogen atom
• R ! is hydrogen or methyl
• R 2 is isopropyl, isobutyl, sec-butyl, tert-butyl, phenyl, benzyl, 1-hydroxyethyl, 4-hydroxybenzyl, 4-hydroxy-3-nitrobenzyl, 4-hydroxy-3-aminobenzyl, 1-phenylethyl, Diphenylmethyl, 1H-imidazol-4-ylmethyl or 1H-indol-3-ylmethyl, or
• # 4 denotes the point of attachment to the adjacent nitrogen atom
• # 5 denotes the point of attachment with the carbonyl group
• ring A with the NO group contained therein for a mono- or bicyclic, optionally substituted heterocycle of the formula
• R 6 is hydrogen, hydroxy or benzyloxy
• R J is hydrogen or methyl
• 4 is isopropyl, isobutyl, sec-Buiyl, tert-butyl, phenyl, benzyl, 1-hydroxyethyl, 4-hydroxybenzyl, 4-hydroxy-3 nitrobenzyl, 4-hydroxy-3-aminobenzyl, 1-phenylethyl, diphenylmethyl, 1H-imidazol-4-ylmethyl or 1/7-indol-3-ylmethyl, or
• R ? for hydrogen, methyl, ethyl, -propyl, fcrr. Butyl, benzyl or adamantylmethyl,
• R 8 is hydrogen or methyl
• R 9 is hydrogen, methyl, ethyl, w-propyl or benzyl, or
• R 8 and R 9 form together with the. Nitrogen atom to which they are attached, a 4- to 7-membered heterocycle,
• R i0 is benzoyl
• R ' 1 for benzyl which may be substituted in the Phenyignippe with metlioxycarbonyl or carboxyl, is hydrogen, methyl or a group of the formula
• R 12 is phenyl which may be substituted by methoxy-carbonyl, carboxy or a group of the formula -S (O) 20H,
• R 13 is phenyl which may be substituted by methoxy-carbonyl or carboxy,
• R 26 is hydrogen or hydroxy
• T 2 is phenyl, benzyl, 1H-indol-3-yl or 1H-indol-3-ylmethyl, R 35 is methyl or hydroxy, and their salts, solvates and solvates of the salts.
• Preferred subject of the invention are Bin der-Wirk Sto f conjugates of general formula (Ia), in which n is a number from 1 to 20, AK for AK, or AK 2 is
• AKi is an antibody or an antigen-binding antibody fragment that binds to mesothelin and is linked to the group G via the sulfur atom of a cysteine residue of the binder,
• AK AK2
• AK2 is carbonyl, for a bond, linear (C -C alkanediyl, a group of the formula where m is a number from 2 to 6,
• ## 1 denotes the point of attachment to the group G which identifies the point of attachment to the group B
• V stands for a bond
• L 6 represents a bond or a group of the formula
• ## 7 denotes the point of attachment with the carbonyl group
• ## 8 denotes the linkage position with L lB
• R 3J is hydrogen, methylcarbonyl or tert-butyloxycarbonyl
• R 34 is hydrogen or methyl
• R 29 is hydrogen
• R 30 is hydrogen
• R 31 is hydrogen or methyl
• R 32 is hydrogen or methyl
• L 1B is linear (C 2 -C 6) -alkanediyl
• R 25 is hydrogen or methyl
• R 28 is hydrogen, metylcarbonyl or tert-butyioxycarbonyi
• R ' a is hydrogen
• R 19 is hydrogen, methyl, propan-2-yl, 2-methylpropan-1-yl or 1-methylpropan-2-yl, 2 0 is hydrogen or methyl, or
• R 21 is hydrogen or methyl
• R 22 is hydrogen or methyl
• R 24 is hydrogen or methyl
• R 2? stands for hydrogen
• R 36 is hydrogen, methylcarbonyl or tert-butyloxyearbonyl
• R 37 is hydrogen or methyl, or R j6 and R J7 together with the atoms to which they are attached form a pyi-tolidine ring, for linear (C 2 -C 6) -alkanediyl or for a group of the formula where p is a number from 2 to 6,
• ## 3 denotes the point of attachment to the group B
• R 1 is hydrogen
• R 2 is 1-hydroxyethyl, benzyl, 4-hydroxybenzyl, 1-phenylethyl or 1H-indol-3-ylmethyl, or
• # 4 denotes the point of attachment to the adjacent nitrogen atom
• # 5 denotes the point of attachment with the carbonyl group
• ring A with the NO group contained therein for a mono- or bicyclic, optionally substituted heterocycle of Fonnel
• # ö denotes the point of attachment to the carbonyl group
• R 6 represents hydrogen, hydroxyl or benzyloxy
• R 3 is hydrogen
• R 4 is 1-hydroxyethyl, benzyl, 4-hydroxybenzyl, 1-phenylethyl or 1H-indol-3-ylmethyl.
• R ? for hydrogen, methyl, ethyl, propyl, terr. Butyl, benzyl or adamantylmethyl,
• R s is hydrogen or methyl
• R 9 is hydrogen, methyl, ethyl, w-propyl or benzyl, or
• R 8 and R 9 form together with the. Nitrogen atom to which they are attached, a 4- to 7-membered heterocycle,
• R i0 is benzoyl
• R ' 1 for benzyl which may be substituted in the phenyl group with metlioxycarbonyl or carboxyl, is hydrogen, methyl or a group of the formula stands in which
• R 12 is phenyl which may be substituted by methoxycarbonyl, carboxyl or a group of the formula -S (0) 2 0H,
• R 13 is phenyl which may be substituted by methoxycarbonyl or carboxyl,
• R 26 is hydrogen or hydroxy
• T 2 is phenyl, benzyl, 1H-indol-3-yl or 1H-indol-3-ylmethyl, R 35 is methyl or hydroxy, and their salts, solvates and solvates of the salts.
• Preferred subject of the invention are binder active ingredient conjugates of the general formula (Ia), in which n is a number from 1 to 20, AK for AK, or AK 2 is
• AKi is an antibody or an antigen-binding antibody fragment which binds to mesothelin and is linked to the group G via the sulfur atom of a cysteine residue of the binder
• linkage site is labeled with the cysteine residue of the binder, + 2 denotes the linkage moiety with the group L '.
• AK AK2
• ## 1 denotes the point of attachment to the group G which identifies the point of attachment to the group B
• L iA is linear (C Cej alkandiy!
• V stands for a bond
• L 6 represents a bond or a group of the formula
• ## 7 denotes the point of attachment with the carbonyl group
• ## 8 denotes the point of attachment to LIB
• R 3J is hydrogen, methylcarbonyl or tert-butyloxycarbonyl
• R 34 is hydrogen or methyl
• R 29 is hydrogen
• R 30 looks for hydrogen
• R 31 is hydrogen or methyl
• R 32 is hydrogen or methyl
• L 1B is linear (C 2 -C 6) -alkanediyl
• L 3 looks for a bond or ethane-l, 2-diyl
• R 28 is hydrogen, methylcarbonyl or tert-butyloxycarbonyl
• Q ! represents a 4- to 7-membered heterocycle
• R is hydrogen
• R 15 is hydrogen
• R 16 is hydrogen or methyl
• R 17 is hydrogen or methyl
• R ' a is hydrogen
• R 19 is hydrogen, methyl, propan-2-yl, 2-methylpropan-1-yl or 1-methylpropan-2-yl, 2 0 is hydrogen or methyl, or
• R 21 is hydrogen or methyl
• R 22 is hydrogen or methyl
• R 24 is hydrogen or methyl
• R 2? stands for hydrogen
• R 36 is hydrogen, methylcarbonyl or tert-butyloxyearbonyl
• R 37 is hydrogen or methyl, or R j6 and R J7 together with the atoms to which they are attached form a pyi-tolidine ring, for linear (C 2 -C 6) -alkanediyl or for a group of the formula where p is a number from 2 to 6,
• ## 3 denotes the point of attachment to the group B
• R 1 is hydrogen
• R 2 is 1-hydroxyethyl, benzyl, 4-hydroxybenzyl, 1-phenylethyl or 1H-indol-3-ylmethyl, or
• # 4 denotes the point of attachment to the adjacent nitrogen atom
• # 5 denotes the point of attachment with the carbonyl group
• ring A with the NO group contained therein for a mono- or bicyclic, optionally substituted heterocycle of Fonnel
• # ö denotes the point of attachment to the carbonyl group
• R 6 represents hydrogen, hydroxyl or benzyloxy
• R 3 is hydrogen
• R 4 is 1-hydroxyethyl, benzyl, 4-hydroxybenzyl, 1-phenylethyl or 1H-indol-3-ylmethyl.
• R ? for hydrogen, methyl, ethyl, -propyl, fcrr. Butyl, benzyl or adamantylmethyl,
• R s is hydrogen or methyl
• R 9 is hydrogen, methyl, ethyl, w-propyl or benzyl, or
• R 8 and R 9 form together with the. Nitrogen atom to which they are attached, a 4- to 7-membered heterocycle,
• R i0 is benzoyl
• R ' 1 for benzyl which may be substituted in the phenyl group with metlioxycarbonyl or carboxyl, is hydrogen, methyl or a group of the formula stands in which
• R 12 is phenyl which may be substituted by methoxy-carbonyl, carboxy or a group of the formula -S (O) 20H,
• R ' 3 is phenyl which may be substituted by methoxycarhonyl or carboxy,
• R 26 is hydrogen or hydroxy
• T 2 is phenyl, benzyl, 1H-indol-3-yl or 1H-indol-3-ylmethyl, R 35 is methyl or hydroxy, and their salts, solvates and solvates of the salts.
• Preferred object of the invention are binder active ingredient conjugates of the general formula (Ia) in which n is a number from 1 to 10, AK for AK, or AK 2 is
• AK- for an antibody comprising the six MFR antibody CDR sequences, the MF-Ta variable light and variable heavy chain variable antibody or the MF-Ta antibody light and heavy chain, which is above the sulfur atom a cysteine residue of the binder is bound to the group G,
• AK for an antibody containing the six CDR sequences of the antibody MF-Ta, the variable light and variable heavy chain of the antibody MF-Ta or the light and heavy chain of the antibody MF-Ta, which is bound to the group G via the NFf side group of a lysine residue of the binder,
• n stands for a number of 2 or 3.
• L 5 is a bond or ethane-1, 2-diyl.
• R z8 is hydrogen, methylcarbonyl or tert-butyioxycarbonyl
• Q 1 is piperidine-1,4-diyl
• R 16 is hydrogen or methyl
• R 17 is hydrogen or meth l
• R '1 is hydrogen or methyl
• R 22 is hydrogen or methyl
• R 23 is methyl
• R 36 is hydrogen, methylcarbonyl or tert-butyloxycarbonyl
• R 37 is hydrogen or methyl, for linear (C -C -alkanediyl or for a group of Fonnei ffv L - ## "
• ## 3 denotes the point of attachment to the group B
• R 1 represents hydrogen
• R 2 is 1-hydroxyethyl, benzyl, 4-hydroxybenzyl, 1-phenylethyl or 1H-indol-3-ylmethyl, above
• # 5 denotes the point of attachment with the carbonyl group, the ring A with the N-0 -group contained therein for a mono- or bicyclic, optionally substituted heterocycle of the formula represents, in which
• # 6 denotes the point of attachment to the carbonyl group
• R 6 is hydrogen, hydroxy or benzyloxy
• R 3 is hydrogen
• R 4 is benzyl, 4-hydroxybenzyl, 1-phenylethyl or 1H-indol-3-ylmethyl, or
• R ' is hydrogen, methyl, ethyl, propyl, tert-butyl, benzyl or adamantylmethyl
• R 8 is hydrogen or methyl
• R 9 is hydrogen, methyl, ethyl, -Propyl or benzyl
• R 11 is benzyl, which may be substituted in the phenyl group with methoxyearbonyl or carboxyl
• R 5 is hydrogen, methyl or a group of the formula stands in which
• R ' 2 is phenyl which may be substituted by methoxyearbonyl, carboxyl or a group of the formula -S (O) 2H,
• R is phenyl which may be substituted with methoxyearbonyl or carboxyl
• R represents methyl or hydroxy, as well as their salts, solvates and solvates of the salts
• Preferred subject matter of the invention are binder-active compound conjugates of the general formula (Ia) in which n is a number from 1 to 10, AK for AK. or AK 2 represents AKi for an antibody comprising the six CDR sequences of the antibody MF-Ta, the antibody MF-Ta variable light and variable heavy chain or the antibody MF-Ta light and heavy chain is bound to the group G via the sulfur atom of a cysteine residue of the binder,
• AK. 2 for an antibody containing the six antibody MF-Ta CDR sequences, the MF-Ta antibody variable light and variable heavy chain or the light heavy chain antibody and heavy chain of the antibody MF-Ta, which is bound to the group G via the NH side group of a lysine residue of the binder,
• n stands for a number of 2 or 3.
• L 3 stands for a bond or ethane 1, 2-diy
• L 4 represents a bond or a group of the formula
• R 25 is methyl
• R 28 is hydrogen, methylcarbonyl or tert-butyloxycarbonyl, Q "is piperidine-1, 4-diyl,
• R ' 6 is hydrogen or meth l
• R is hydrogen or methyl
• R 22 is hydrogen or methyl
• R i4 is hydrogen. for linear (Cz-Cöi-alkanediyl or for a group of the formula where stands for a number from 2 to 6.
• R ' is hydrogen
• R is 1-hydroxyethyl, benzyl, 4-hydroxybenzyl, 1-phenylethyl or W-indol-3-ylmethyl, see above
• # 3 denotes the point of attachment to the carbonyl group, the ring A with the NO grapping contained therein for a mono- or bicyclic, optionally substituted heterocycle of the formula
• # 6 denotes the linking moieties with the carbonyl group, for hydrogen. Sees hydroxy or benzyloxy,
• R 3 is hydrogen
• R 4 is benzyl, 4-hydroxybenzyl, 1-phenylethyl or 1H-indol-3-ylmethyl, or R J and R 4 together with the carbon atom to which they are attached form a (IS, 2R) -2-phenylcyclopropane-1,1-diyl group of the formula
• R 7 is hydrogen, methyl, ethyl, propyl, tert-butyl, benzyl or adamantylmethyl,
• R 8 is hydrogen or methyl
• R 9 is hydrogen, methyl, ethyl, propyl or benzyl
• R ' 1 for benzyl which may be substituted in the phenyl group with methoxycarbonyl or carboxyl, is hydrogen, methyl or a group of the formula stands in which
• R 9 denotes the linking site with -CHCH-phenyl, represents phenyl which may be substituted by methoxycarbonyl, carboxyl or a group of the formula -Si'Oj OH, R ' 3 is phenyi which may be substituted by methoxycarbonyi or carboxyl,
• R 35 is methyl or hydroxy, and their salts, solvates and solvates of the salts.
• Preferred subject matter of the present invention are binder-active compound conjugates of general formula (Ia) as indicated above, in which n is a number from 1 to 10,
• AK stands for AK 2 , where
• AK2 for an antibody comprising the six MFR antibody CDR sequences, the MF-Ta variable light and variable heavy chain antibody or the MF-Ta antibody light and heavy chain, and the NH side group a lysine residue of the binder is bound to the group G,
• G is carbonyl
• ## 3 denotes the point of attachment to the group B
• R 2 is benzyl, 4-hydroxybenzyl or 1H-indol-3-ylmetliyl, or
• the ring A having the N-0 -group contained therein for a mono- or bicyclic, optionally substituted heterocycle of the formula
• R 3 is hydrogen
• R 4 is benzyl, 4-hydroxybenzyl or 1H-indol-3-ylmethyl, or
• R 7 is hydrogen, methyl, ethyl, isopropyl, tert-butyl, benzyl or adamantylmethyl,
• R 8 is hydrogen
• R 9 is hydrogen or benzyl
• R 35 is methyl
• Preferred subject of the invention are binder active ingredient conjugates of the general formula (Ta), in which n is a number from 1 to 10, for AK 2 is where
• AK.2 for an antibody comprising the six MFR antibody CDR sequences, the MF-Ta variable light and variable heavy chain antibody or the MF-Ta antibody antibody light and heavy chain, crossing the NH - Side group of a lysine residue of the binder is bound to the graft G, is carbonyl, represents a bond, represents, represents a bond, linear (Ci-CeVAlkaodiyl or a group of the formula where p is a number of 2 or 3, ## 3 denotes the point of attachment to the group B,
• # 3 denotes the point of attachment to the nitrogen atom
• R 1 is hydrogen, is benzyl or 1H-indol-3-ylmethyl. or
• # 5 denotes the point of attachment with the carbonyl group, the ring A with the N-0 -group contained therein for a mono- or bicyclic, optionally substituted heterocycle of the formula
• R 3 is hydrogen. is benzyl or 1H-indol-3-ylmethyl, oaer
• R 7 is hydrogen, methyl, ethyl, r-propyl, tert-butyl, benzyl or adamantylmethyl,
• R 8 is hydrogen
• R 9 is hydrogen or benzyl
• R 35 is methyl
• Preferred subject matter of the present invention are binder-active compound conjugates of the general formula (Ia) as indicated above, in which n is a number from 1 to 10,
• AK stands for AKi, where
• AK-. for an antibody comprising the six CDR sequences of the MF-Ta antibody, the MF-Ta variable light and variable heavy chain antibody or the MF-Ta antibody light and heavy chain, which is linked to the sulfur atom of a cysteine Rest of the binder is bound to the gib G, for a group de
• n stands for a number of 2 or 3.
• ## 1 denotes the point of attachment to the group G.
• (C3-C5) -alkanediyl may be substituted with 1 or 2 substituents methyl, for a bond or a group of the formula
• L J is a bond or ethane-l, 2-diyl, L 4 represents a bond or a group of the formula
• R 25 is methyl
• R 28 is hydrogen, methylcarbonyl or tert-butyloxycarbonyl
• R ' 6 is hydrogen or methyl
• R 17 is hydrogen or methyl
• R 2 is benzyl, 4-hydroxybenzyl or 1H-indol-3-ylmethyl, or
• the ring A having the -0-grouping contained therein for a mono- or bicyclic, optionally substituted heterocycle of the formula
• R 3 is hydrogen
• R 4 is benzyl, 4-hydroxybenzyl or 1H-indol-3-ylmethyl, or
• R 7 is hydrogen, methyl, ethyl, propyl, tert-butyl, benzyl or adamantylmethyl,
• R 8 is hydrogen
• R 9 is hydrogen or benzyl
• R 35 is methyl
• Preferred subject of the invention are binder active ingredient conjugates of the general formula (Ta), in which n is a number from 1 to 10, AK stands for AKi
• AKi for an antibody comprising the six MFR antibody CDR sequences, the MF-Ta variable light and variable heavy chain antibody or the MF-Ta antibody light and heavy chain, is via the sulfur atom of a cysteine Residue of the binder is bound to the group G,
• G is a group of the formula
• # 'de denotes the point of attachment to the cysteine residue of the binder
• # 2 denotes the point of attachment to the group L 1
• L 1 represents a bond, linear (C 1 -C 8) -alkanediyl or a group of the formula where m is a number of 2 or 3
• L 3 is a bond or ethane-l
• 2-diyl L 4 is a bond or a group of the formula
• R 28 is hydrogen, methylcarbonyl or tert-butyloxycarbonyl, R li! is hydrogen or methyl, R 1 'is hydrogen or methyl, or
• ## 3 denotes the point of attachment to the group B
• R 1 is hydrogen
• R 2 is benzyl or 1H-indol-3-ylmethyl, or
• R 3 is hydrogen
• R 4 is benzyl or 1H-indol-3-ylmethyl
• R 7 is hydrogen, methyl, ethyl, propyl, tert-butyl, benzyl or adamantylmethyl
• R 9 is hydrogen or benzyl
• R 35 is Methvl, and their salts, solvates and solvates of the salts.
• Another object of the present invention are compounds of the formula (XXXa)
• XXa in which represents a cysteine residue which is bonded via the sulfur atom of the side chain carbon atom of the succinimide, for a bond, linear (G -o) -alkandyl, a group of the formula
• ## 1 denotes the point of attachment to the group G
• A is linear ⁇ G-Go) alkanediyl
• R 29 is hydrogen or (C 1 -C 4) -alkyl
• R J0 is hydrogen or (Ci-G-alkyl, or
• R 29 and R J 0 together with the atoms to which they are attached form a 5- or 6-membered heterocycle
• R J1 is hydrogen or (Ci-G-alkyl
• R 32 is hydrogen or (C 1 -C 4 ) -alkyl, or
• R 31 and R 3i together with the atoms to which they are attached form a 5- or 6-membered heterocycle
• L iB is linear (C 2 -C 10) -alkanediyl, and wherein (C 1 -C 10) -alkanediyl having 1 to 4 substituents independently of one another can be substituted from the group consisting of methyl, hydroxy and benzyl, unc with two carbon atoms of the alkanediyl Chain in 1,2-, 1,3- or 1, 4-relation to each other, including the carbon atoms optionally between them can be bridged to a (C3-Ce) -cycloalkyl ring or a phenyl ring, for a bond or a group of the formula
• L 3 is a bond or (C 1 -C 4 -alkanediyl, L 4 is a bond,
• Q 1 is a 4- to 7-membered heterocycle
• Q 2 is a 3- to 7-membered carbocycle or a 4- to 7-membered heterocycle
• R 14 is hydrogen or (C 1 -C 4 ) -alkyl
• R 15 is hydrogen or (C 1 -C 4 -alkyl
• R 14 and R 15 together with the atoms to which they are attached form a 5- or 6-membered heterocycle
• R ! 6 is hydrogen or (C 1 -C 4 ) -alkyl
• R 17 is hydrogen or (Ci-C4) -alkyl, or R 16 and R 17 together with the atoms to which they are attached form a 5- or 6-membered heterocycle,
• R 18 is hydrogen or (C 1 -C 4 ) -alkyl
• R 19 represents hydrogen or the side group of a natural ⁇ -amino acid or its homologs or isomers
• R 20 is hydrogen or (C 1 -C 4 ) -alkyl, or
• R 21 is hydrogen or (C 1 -C 4 ) -alkyl
• R 22 is hydrogen or (Ci-CVi-alkyl, or
• R 2i and R 22 together with the atoms to which they are attached form a 3- to 7-membered carbocycle, R 23 is (C 1 -C 4 ) -alkyl,
• R 24 is hydrogen or (C 1 -C 4 ) -alkyl
• R 27 is hydrogen or (Ci-C 4 ) alkyl, linear (C -CioVAlkandiyl or a group of the formula where p is a number from 2 to 6,
• ## 4 denotes the point of attachment to the nitrogen atom
• (CVCio) alkanediyl may be substituted with 1 to 4 substituents independently selected from the group of methyl, hydroxy and benzyl, and wherein two carbon atoms of the alkanediyl chain in 1, 2, 1, 3 or 1.4 ratio with respect to each other, including the carbon atoms which may be present between ilines, may be bridged to form a (C 1 -C 6 -cycloalkyl ring or a phenyl ring,
• # J denotes the point of attachment to the nitrogen atom
• R 1 is hydrogen or methyl
• R 2 isopropyl, isobutyl, sec-butyl, tert-butyl, phenyl, benzyl, 1-hydroxyethyl, 4-hydroxybenzyl, 4-hydroxy-3-nitrobenzyl, 4-hydroxy-3-aminobenzyl, 1-phenyl ethyl, diphenylmethyl, 1H-imidazol-4-ylmethyl or 1H-indol-3-ylmethyl, or
• # 5 denotes the linkage site with the carbonyi group, the ring A with the -O-moiety contained therein for a mono- or bicyclic, optionally substituted heterocycle of the formula
• R 6 is hydrogen, hydroxy or benzyloxy
• R 3 is hydrogen or methyl
• R 4 is isopropyl, isobutyl, sec-butyl, tert-QaXyl, phenyl, benzyl, 1-hydroxyethyl, 4-hydroxybenzyl, 4-hydroxy-3-nitrobenzyl, 4-hydroxy-3-aminobenzyl, 1-phenylethyl , Diplienylmethyl, 1H-imidazol-4-ylmethyl or 1H-indol-3-ylmethyl, above
• # 7 identifies the linkage site with the adjacent nitrogen atom
• R 7 is hydrogen, methyl, ethyl, propyl, f is-butyl, benzyl or adamantylmethyl,
• R s is hydrogen or methyl
• R 9 is hydrogen, methyl, ethyl, w-propyl or benzyl, or
• R 8 and R 9 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycle
• R '° represents benzoyl
• R ' 1 for benzyl which may be substituted in the phenyl group with methoxycarbonyl or carboxyl, is hydrogen, methyl or a group of the formula
• # 9 denotes the point of attachment with -CHC (R 26 ) ⁇ T
• R 12 is phenyl which may be substituted by methoxycarbonyl, carboxyl or a group of the formula ⁇ S (0) 2 0H,
• R ' 3 is phenyl which may be substituted by methoxycarbonyl or carboxyl
• R 6 is hydrogen or hydroxy
• T 2 is phenyl, benzyl, 1H-indol-3-yl or 1H-indol-3-ylmethyl,
• R 35 is methyl or hydroxy, and their salts, solvates and solvates of the salts. Also preferred in the context of the present invention are compounds of the formula (XXXa) in which
• Cys represents a cysteine residue which is linked via the sulfur atom of the side chain via a carbon atom of the succinimide
• ## 1 indicates the point of linkage with the group G
• ## 2 indicates the point of linkage with the group B
• L lA is linear (CVCej-Alkandiy!
• B 1 represents a Grappas of formula
• ## 5 denotes the point of attachment to the group L ' A
• ## 0 denotes the point of attachment to the group L' B
• L 5 represents a bond
• R 29 is hydrogen
• R 30 is hydrogen
• R 3 ' is hydrogen or methyl
• R 32 is hydrogen or methyl
• L 1B is linear (Cz-Cö alkanediyl
• L 3 is a bond or ethane-l, 2-diyl
• R 13 is hydrogen
• R ! 6 is hydrogen or methyl
• R 17 is hydrogen or methyl
• R 23 is methyl
• R 24 is hydrogen or methyl
• L z is linear (C 2 -C 6) alkanediyl or a group of formula where p is a number of 2 or 3,
• ## 3 denotes the point of attachment to the group B
• R 2 is 1-hydroxyethyl, benzyl, 4-hydroxybenzyl, 1-phenylethyl or 1-tf-indol-3-yl methyl, above R 1 and R 2 together with the carbon atom to which they are attached form a (15,2R) -2-phenylcyclopropane-1,1-diyl group of the formula
• # 5 denotes the point of attachment with the carbonyl group, the ring A with the N-0 -group contained therein for a mono- or bicyclic, optionally substituted heterocycle of the formula
• # 6 identifies the point of attachment with the carbonyl group. is hydrogen, hydroxy or benzyloxy,
• R 3 is hydrogen, 1-hydroxyethyl, benzyl, 4-hydroxybenzyl, 1-phenylethyl or 1H-indole-methvl, see above
• R ? represents hydrogen, methyl, ethyl, propyl, tert-butyl, benzyl or adamantylmethyl
• R 8 is hydrogen or methyl
• R 9 is hydrogen, methyl, ethyl, w-propyl or benzyl, or
• R 8 and R 9 form together with the. Nitrogen atom to which they are attached, a 4- to 7-membered heterocycle,
• R i0 is benzoyl
• R ' 1 for benzyl which may be substituted in the Phenylgnippe with metlioxycarbonyl or carboxyl, is hydrogen, methyl or a group of the formula stands in which # 9 identifies the point of attachment with -CHCFfaPhenyl,
• R 12 is phenyl which may be substituted by methoxycarbonyl, carboxy or a group of the formula -S (O) 20H,
• R is phenyl which may be substituted by methoxycarbonyl or carboxyi
• R 35 is methyl or hydroxy, and their salts, solvates and solvates of the salts,
• Cys represents a cysteine residue which is linked via the sulfur atom of the side chain via a carbon atom of the succinimide
• L 1 is a bond or linear (Ci-Csj-Alkandiyi stands,
• L 3 is a bond
• R ! 6 is hydrogen or methyl
• R 17 is hydrogen or methyl, linear (C 2 -C 6) alkanediyl or a group of. where p is a number of 2 or 3,
• ## 3 denotes the linking parts with the group B
• R 1 is hydrogen
• R is benzyl or 1H-indo-3-ylmethyl, or
• R 1 and R 2 together with the carbon atom to which they are attached
• # 5 denotes the linkage site with the carbonyl group, the ring A with the -O-moiety contained therein for a mono- or bicyclic, optionally substituted heterocycle of Fonnel
• R 3 is hydrogen
• R 4 is benzyl or 1 H-Tndol-3-ylmethyl
• R 8 is hydrogen
• R v is hydrogen
• R is methyl, and their salts, solvates and solvates of the salts.
• Cys is a cysteine radical which is attached via the sulfur atom of the side chain via a carbon atom of the succinimide, L 1 is a bond or linear (Ci-Ce aikandiyl stands,
• L 3 is a bond
• R 16 is hydrogen or methyl
• R 17 is hydrogen or methyl
• L 2 is linear -C) alkanediyl or a group of the formula where p is a number of 2 or 3,
• ## 3 denotes the point of attachment to the group B
• # - s denotes the point of attachment to the carbonyl group, the ring A with the -O-moiety contained therein for a mono- or bicyclic, optionally substituted heterocycle of the formula
• R 3 is hydrogen
• R 4 is benzyl, 4-hydroxybenzyl or 1H-indol-3-ylmethyl, or
• R 7 is hydrogen
• R s is hydrogen
• R 9 is hydrogen
• R 35 is methyl
• Another object of the present invention are compounds of formula (XXXI)
• n is a number from 2 to 6
• ## 1 denotes the connection point with the group G
• A is linear (C 2 -C 10) -alkanediyl
• R 29 is hydrogen or stands
• R 30 is hydrogen or (C 1 -C 4) -alkyl, or
• R 29 and R 30 together with the atoms to which they are attached form a 5- or 6-membered heterocyci
• R 31 is hydrogen or (C 1 -C 4 -alkyl
• R J2 is hydrogen or (Ci-G alkyl, or
• R 31 and R J together with the atoms to which they are attached form a 5- or 6-membered heterocyci
• L lB is linear (C 2 -C 10) -alkanediyl, and wherein (C 1 -C 10) -alkanediyl may be substituted with 1 to 4 substituents independently selected from the group of methyl, hydroxy and benzyl, and wherein two carbon atoms of the alkanediyl chain in 1, 2, 1, 3 or 1,4 relative to one another, including the carbon atoms which may be present between them, may be bridged to form a (Cs-CeVcycloalkyl ring or a phenyl ring, for a bond or a group of the formula
• Q- represents a 3- to 7-membered carbocycle or a 4- to 7-membered heterocycle
• R 18 is hydrogen or (C 1 -C 4) -alkyl
• R 1 is hydrogen or the side group of a natural ⁇ -amino acid or its homologs or isomers
• K is hydrogen or (Ci-C 4 ) -alkyl
• R 2! is hydrogen or (C 1 -C 4 ) -alkyl
• R 22 is hydrogen or (Ci-C 4 ) -alkyl, or R 1 and R 2 together with the atoms to which they are attached form a 3-membered carbocycle,
• R 27 is hydrogen or (C 1 -C 4 ) -alkyl, linear (C ' 2-Cio) -alkanediyl or a group of the formula where p is a number from 2 to 6,
• ## 3 denotes the point of attachment to the group B
• (C 1 -C 10) -alkanediyl having 1 to 4 substituents independently of one another can be substituted by the formula methyl, hydroxy and benzyl, and where two carbon atoms of the alkanediyl chain are present in 1, 2, 1, 3 or 1, 4-Relaüu each other, including the optionally intervening carbon atoms can be bridged to a (Ca-Chj-cycloalkyl ring or a phenyl ring, for a group of the formula
• R ! is hydrogen or methyl
• R is isopropyl, isobutyl, sec-butyl, terr-butyl, phenyl, ⁇ -benzyl, 1-hydroxyethyl, 4-hydroxybenzyl, 4-hydroxy-3-nitrobenzyl, 4-hydroxy-3-aminobenzyl, 1-phenylethyl, Diphenylmethyl, 1H-imidazol-4-ylmethyl or 1H-indol-3-ylmethyl, or
• # 5 denotes the point of attachment with the carbonyl group, the ring A with the N-0 group contained therein for a mono- or bicyclic, optionally substituted Ileterocyclus of Fonnel
• R 6 is hydrogen, hydroxy or benzyloxy
• R 3 is hydrogen or methyl
• R 4 is isopropyl, isobutyl, sec-butyl, terr-butyl, phenyl, benzyl, 1-hydroxyethyl, 4-hydroxybenzyl, 4-hydroxy-3-nitrobenzyl, 4-hydroxy-3-aminobenzyl, 1-phenylethyl , Diphenylmethyl, 1H-imidazol-4-ylmethyl or 1H-indol-3-ylmethyl, or
• R 8 is hydrogen or methyl
• R 9 is hydrogen, methyl, ethyl, n-propyl or benzyl, or R 8 and R 9 together with the nitrogen atom to which they are attached form a 4- to 7-membered ileterocycle,
• R 10 is benzoyl
• R ' 1 represents benzyl which may be substituted in the phenyl group by methoxyearbonyl or carboxyi
• R ⁇ is hydrogen, methyl or a group of the formula
• # 9 identifies the point of attachment with -CHC (R 26 ) -T 2 ,
• R 52 is phenyi which may be substituted with methoxyearbonyl, carboxyi or a group of the formula -S (0) 2 0H. is phenyi which may be substituted with methoxyearbonyl or carboxyi
• R 26 is hydrogen or Hydroxv. is phenyl, benzyl, 1H-indol-3-yl or 1H-indol-3-ylmethyl,
• R 35 is methyl or hydroxy, and their salts, solvates and solvates of the salts.
• preference is also given to compounds of the formula (XXXI) in which
• L 1 is a bond, linear (C 2 -C 6) alkanediyl or a group of the formula where m is a number of 2 or 3, ## 'is the point of attachment to the group G denotes, ## 2 indicates the point of linkage with the group B, (Ca-GYhAlkandiyi methyl substituents may be substituted in with ⁇ or 2, a bond or a group of the coliforms:
• R 19 is methyl, propan-2-yl, 2-ethyl-propan-1-yl or i-methyl-propan-1-yl,
• R 20 is hydrogen or (CC 4 ) -alkyl, or
• R 21 is hydrogen or methyl
• R is hydrogen or methyl
• R 2i and R 22 together with the atoms to which they are attached form a cyclopropyl ring, is hydrogen or methyl, linear (C2-C6) -anediyl or a group of the formula stands, where
• P is a number of 2 or 3
• ## 3 denotes the point of attachment to the group B
• (C 2 -C 10) -alkanediyl may be substituted by 1 or 2 subsituents of methyl, and in which two carbon atoms of the alkanediyl chain may be bridged in 1,4-relation to each other, including the carbon atoms which may be present between them, to form a phenyl ring,
• # J denotes the point of attachment to the nitrogen atom
• R 1 is hydrogen
• R 2 is 1-hydroxyethyl, benzyl, 4-hydroxy-benzyl, 1-phenylethyl or 1 7-indol-3-yl-methyl, or R 1 and R 2 together with the carbon atom to which they are attached form a (1S, 2R) -2-phenylcyclopropane-1,1-diyl group of the formula
• # 5 denotes the linking moieties with the carbonyi group, the ring A with the N-0 moiety contained therein for a monocyclic or bicyclic, optionally substituted heterocycle of the formula
• R 6 is hydrogen, hydroxy or benzyloxy
• R 3 is hydrogen
• R 4 is ⁇ -hydroxyethyl, benzyl, 4-hydroxybenzyl, i-phenylethyl or lH-indol-3-yl-methyl, or
• R ? for hydrogen, methyl, ethyl, -propyl, fcrr. Butyl, benzyl or adamantylmethyl,
• R s is hydrogen or methyl
• R 9 is hydrogen, methyl, ethyl, w-propyl or benzyl, or
• R 8 and R 9 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycle
• R i0 is benzoyl
• R ' 1 for benzyl which may be substituted in the phenyl group with metlioxycarbonyi or carboxyl, is hydrogen, methyl or a group of the formula stands in which # denotes the linkage point with -CHCFfePhenyl,
• R i2 is phenyl which is reacted with metlioxycarbonyl, carboxyi or a group of the formula -S (O) ? .OH may be substituted. is phenyl which may be substituted with metlioxycarbonyl or carboxyi,
• R 35 is methyl or hydroxy, and their salts, solvates and solvates of the salts.
• L 2 represents linear (C 2 -C 6) -alkanediyl or a group of the formula stands, where
• P is a number of 2 or 3
• R 1 is hydrogen
• R 2 is benzyl or 1 / -indol-3-ylmethyl, or
• # - s denotes the linkage with the Carbonyi group, the ring A with the N-0 moiety contained therein for a monocyclic or bicyclic, optionally substituted heterocycle of the formula
• # 6 denotes the point of attachment to the carbonyi group, R 6 is hydrogen, hydroxy or benzyloxy,
• R 3 is hydrogen
• R 4 is benzyl or 1H-indol-3-ylmethyl
• R J and R 4 together with the carbon atom to which they are attached form a (IS, 2R) -2-phenylcyclopropane-1,1-diyl group of the formula
• R 7 is hydrogen
• R 8 is hydrogen
• R 9 is hydrogen, R 35 is methyl, and their salts, solvates and solvates of the salts.
• L 1 is a bond
• ## 3 denotes the point of attachment to the group B
• R z is benzyl, 4-hydroxybenzyl or 1H-indol-3-ylmethyl, or
• # ö denotes the point of attachment to the carbonyl group
• R 6 is hydrogen, hydroxy or benzyloxy
• R J is hydrogen
• R 4 is benzyl, 4-hydroxybenzyl or 1 // -indol-3-ylmethyl, or
• R ? is hydrogen
• R 8 is hydrogen
• R 9 is hydrogen
• R 35 represents methyl, and their salts, solvates and solvates of the salts.
• a further subject of the present invention are binder active compound conjugates of the general formula (I)
• n is a number from 1 to 50.
• AK stands for a binder, the group ⁇ -GL 1 -BL 2 - ⁇ is a linker, where
• ⁇ denotes the association with the group AK
• R 1 is hydrogen, 1-hydroxyethyl, benzyl, 1-phenylethyl or 1H-indol-3-ylmethyl, oaer
• # 5 denotes the point of attachment with the Carbonyi group, the ring A with the -O-Gnipêt contained therein for a mono- or bicyclic, optionally substituted heterocycle of the formula
• R 6 is hydrogen, hydroxy or benzyloxy
• R 3 is hydrogen
• R 4 is 1-hydroxyethyl, benzyl, 1-phenylethyl or 1H-indol-3-ylmethyl, or
• R ? for hydrogen, methyl, ethyl, propyl, tert. Butyl, benzyl or adamantylmethyl,
• R s is hydrogen or methyl
• R 9 is hydrogen, methyl, ethyl, propyl or benzyl, or
• R 8 and R 9 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycle
• R i0 is benzoyl
• R ' 1 for benzyl which may be substituted in the Phenylgnippe with methoxycarbonyl or carboxy, stands for hydrogen, methyl or a group of the formula
• # 9 identifies the point of attachment with -CHC (R 2ö ) -T i ,
• R ' 2 is phenyl which may be substituted by methoxycarbonyl, carboxyi or a group of the formula -SiOj OH,
• R 13 is phenyl which may be substituted by methoxycarbonyl or carboxy, represents hydrogen or hydroxy
• T 2 is phenyl, benzyl, 1H-indol-3-yl or 1H-indol-3-ylmethyl, and their salts, solvates and solvates of the salts.
• Preferred subject matter of the invention are binder-active compound conjugates of the general formula (I) in which n is a number from 1 to 50,
• AKi for a binder bound to the group G via a sulfur atom of the binder
• AK2 for a binder bound to the group G via a nitrogen atom of the binder
• # 'de notes the point of attachment to the sulfur atom of the binder

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Immunology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biochemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Molecular Biology (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Cell Biology (AREA)
• Crystallography & Structural Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Oncology (AREA)
• Reproductive Health (AREA)
• Gastroenterology & Hepatology (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Endocrinology (AREA)
• Hematology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Indole Compounds (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Priority Applications (3)

Applications Claiming Priority (24)

Related Parent Applications (1)

Related Child Applications (1)

Publications (2)

Family

ID=45976407

Family Applications (4)

Family Applications After (3)

Country Status (16)

Cited By (15)

Families Citing this family (54)

Citations (76)

Family Cites Families (31)

• 2012
  • 2012-04-20 BR BR112013027119A patent/BR112013027119A8/pt not_active IP Right Cessation
  • 2012-04-20 SG SG2013078282A patent/SG194567A1/en unknown
  • 2012-04-20 CN CN201280028243.5A patent/CN103764170A/zh active Pending
  • 2012-04-20 KR KR1020137030468A patent/KR20140122649A/ko not_active Withdrawn
  • 2012-04-20 CN CN201280019602.0A patent/CN103826661B/zh not_active Expired - Fee Related
  • 2012-04-20 WO PCT/EP2012/057249 patent/WO2012143499A2/de not_active Ceased
  • 2012-04-20 CN CN201610450907.7A patent/CN106117312A/zh active Pending
  • 2012-04-20 SG SG10201702384PA patent/SG10201702384PA/en unknown
  • 2012-04-20 WO PCT/EP2012/057243 patent/WO2012143495A2/de not_active Ceased
  • 2012-04-20 KR KR1020137030493A patent/KR102023496B1/ko not_active Expired - Fee Related
  • 2012-04-20 WO PCT/EP2012/057245 patent/WO2012143496A2/de not_active Ceased
  • 2012-04-20 AU AU2012244673A patent/AU2012244673A1/en not_active Abandoned
  • 2012-04-20 RU RU2013151600A patent/RU2610336C2/ru not_active IP Right Cessation
  • 2012-04-20 AU AU2012244675A patent/AU2012244675B2/en not_active Ceased
  • 2012-04-20 AR ARP120101371A patent/AR086363A1/es unknown
  • 2012-04-20 CA CA2833690A patent/CA2833690A1/en not_active Abandoned
  • 2012-04-20 US US13/451,916 patent/US20130122024A1/en not_active Abandoned
  • 2012-04-20 JP JP2014505642A patent/JP6088488B2/ja not_active Expired - Fee Related
  • 2012-04-20 US US13/451,950 patent/US20130066055A1/en not_active Abandoned
  • 2012-04-20 TW TW101114203A patent/TWI582112B/zh not_active IP Right Cessation
  • 2012-04-20 MX MX2013012253A patent/MX2013012253A/es active IP Right Grant
  • 2012-04-20 TW TW106103491A patent/TWI636793B/zh not_active IP Right Cessation
  • 2012-04-20 AR ARP120101372A patent/AR086364A1/es unknown
  • 2012-04-20 JP JP2014505641A patent/JP2014515753A/ja not_active Withdrawn
  • 2012-04-20 RU RU2013151599/04A patent/RU2013151599A/ru not_active Application Discontinuation
  • 2012-04-20 EP EP12718624.5A patent/EP2699268A2/de not_active Withdrawn
  • 2012-04-20 WO PCT/EP2012/057247 patent/WO2012143497A2/de not_active Ceased
  • 2012-04-20 EP EP19150066.9A patent/EP3501546A3/de not_active Withdrawn
  • 2012-04-20 CA CA3027793A patent/CA3027793A1/en not_active Abandoned
  • 2012-04-20 CA CA2833477A patent/CA2833477A1/en not_active Abandoned
  • 2012-04-20 US US14/113,070 patent/US20140127240A1/en not_active Abandoned
  • 2012-10-20 US US13/656,681 patent/US8992932B2/en not_active Expired - Fee Related
• 2013
  • 2013-10-13 IL IL228841A patent/IL228841A/en active IP Right Grant
  • 2013-10-24 ZA ZA2013/07955A patent/ZA201307955B/en unknown
• 2014
  • 2014-05-05 US US14/269,577 patent/US20150030618A1/en not_active Abandoned
• 2015
  • 2015-05-11 US US14/708,914 patent/US20150246136A1/en not_active Abandoned
• 2016
  • 2016-02-24 US US15/052,655 patent/US20160193359A1/en not_active Abandoned
  • 2016-05-31 JP JP2016109316A patent/JP6250735B2/ja not_active Expired - Fee Related
  • 2016-09-26 IL IL248036A patent/IL248036B/en active IP Right Grant
• 2017
  • 2017-06-09 AU AU2017203928A patent/AU2017203928B2/en not_active Ceased

Patent Citations (81)